Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea (SIX: BSLN): another Cresemba milestone payment
Published by Arron Aatkar, PhD

Basilea Pharmaceutica has announced that the continued strong sales of Cresemba (isavuconazole, the copmany’s lead antifungal therapy)has triggered the second US$2.5m payment of the year. This milestone payment comes from Pfizer, based on the license agreement between the companies which covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific Region.

Cresemba is marketed in over 70 countries. According to the latest available data, total global in-market sales of Cresemba in the 12-month period between January and December 2024 amounted to US$562m, a 19% growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.